Moleculin Biotech Inc (MBRX) Institutional Buying & Selling Tracker (Q2 2026)

MBRX ranks #8659 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

18 institutions disclose a position in MBRX, but none treat it as a major bet — even Geode Capital Management, LLC, its most concentrated holder, allocates just 0.0% of its own portfolio to it.

MBRX reported a net loss of $30.3M over the trailing twelve months.

• Not yet profitable — net loss of $30.3M over the trailing twelve months
• Net income improved year over year, from -$36.9M to -$30.3M
• Operating cash flow was negative, using $22.7M in cash
• Current ratio of 1.41x — below the conventional 1.5x liquidity buffer
• Liabilities run 0.47x equity — within a conventional range